Sunday, November 3, 2024

Challenges and Opportunities for the Pharmaceutical Industry in 2024: A GlobalData Report

Similar articles

Subscribe Weekly Market Access News

* indicates required

Inflation, geopolitical conflict, and drug pricing pressures are identified as key challenges in the pharmaceutical industry in a survey by GlobalData. Economic uncertainty, potential disruptions to the IPO market, and economic sanctions are the potential repercussions of these challenges, especially inflation and geopolitical tensions. Drug pricing, largely influenced by regulatory trends, is considered the most detrimental, potentially impeding industry growth.

The impact of price controls in significant markets is highlighted, as they prevent drug prices from rising in tandem with general inflation. This could restrict revenue growth for pharmaceutical companies, particularly as production costs may rise significantly due to increased supplier costs and employee wage expectations.

Challenges and Opportunities in the Pharmaceutical Industry’s Path Forward

However, the GlobalData report also points out positive influences for the industry, including Environmental, Social, and Corporate Governance (ESG) factors and the patent expiration of biologics. The latter is expected to contribute to the streamlining of operations and promotion of growth.

To succeed in the face of these challenges, the pharmaceutical industry is encouraged to innovate and enhance resilience. Strategies such as modernizing R&D models and implementing emerging technologies are suggested to secure a competitive advantage.

Pharmaceutical Industry

Key Factors Shaping the Pharmaceutical Industry’s Future

The report also mentions two emerging industry trends: the development of immuno-oncology drugs and the use of real-world evidence (RWE). These trends are anticipated to steer the future direction of the biopharmaceutical industry.

Despite the identified challenges, opportunities exist within the pharmaceutical industry, including the patent expiration of biologics, the development of immuno-oncology drugs, and the use of real-world evidence. These factors, along with strategies such as innovation, resilience enhancement, and modernization of R&D models, could help the industry maintain growth and competitiveness.


This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Latest article